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The role of the kinin-forming system in inflammatory injury is not well understood 
Its role in pathologic states has been assessed generally in plasma or plasma-rich fluids 
by association of free kinin with inflammatory conditions, by a  decrease in kininogen 
levels (1), or by measurement of esterase activities (2). The interpretation of results in 
such studies has been made difficult by the extremely short life-span of kinins and by 
the  instability of precursor components.  Once  activated,  the  components react se- 
quentially during the preparation of samples, and are rapidly affected by inhibitors in 
the plasma. 
In an assessment of the role that members of this system might play in the patho- 
genesis of various diseases, it has become necessary to isolate each component of the 
plasma kinin-forming system in precursor or inactive form. In so doing, one may be 
able  to  determine  the  exact  number  of  components  in  the  system,  to  study  their 
interactions and mechanisms of activation, and to  see if potentially important side 
products result during the process of activation. With precursor components available, 
their turnover times and participation in pathologic states could be assessed. In ad- 
dition, since the kinin-forming system and intrinsic clotting system are apparently 
related, the role of the clotting system in inflammation will be subject to investigation. 
The  present  article  describes  the  preparation  and  characterization  of  the 
first  component  of  the  kinin-forming  system  in  rabbit  and  htanan  plasma. 
The process of activation is analyzed. 
We  have  selected the  following  terminology  on  the  basis  of  enzyme-sub- 
* Publication No.  522  from  the Department of Experimental Pathology, Scripps  Clinic 
and Research Foundation, La Jolla, Calif. 92037. The work was supported by U.  S. Public 
Health Service grant AI-07007, The National Multiple Sclerosis Society,  The Council  for 
Tobacco Research,  USA, and the American Heart Association. 
:~ Recipient of U.  S.  Public Health  Service  Research  Career Development  Award  No. 
1  K4  AM 40,086-01. 
986  THE  JOURNAL OF  EXPERIMENTAL MEDICINE • VOLUME 134,  1971 c.  G.  COCHRANE  AND  K.  D.  WUEPPER  987 
strate reactions assigning functional names to each component: 
precursor of the prekallikrein activator (Pre-PKA) 1 
(Hageman factor) 
(clotting factor XII) 
prekallikrein 
(prokininogenase) 
activator 
>prekailikrein activator (PKA) 
P 
I  ~kallikrein 
(kininogenase) 
__! 
kininogen  ~  kinin 
Materials and Methods 
Blood was obtained from rabbits, normal human volunteers, and an individual  2 known to 
be deficient in clotting factor XII (Hageman factor). The factor XII-deficient plasma failed 
to correct the clotting defect of other factor XII-deficient plasma, but did correct the defect 
in factor XI-deficient plasma (for assays of clotting activity, see below). The blood was col- 
lected through siliconized needles from the ear artery of rabbits or the anti-cubital vein of 
human beings directly into plastic tubes containing acid-citrate anticoagulant  (ACD).  Gen- 
eraily, 1 liter of rabbit blood or 500 ml of human blood were collected at one time. The formed 
elements were centrifuged away at 3500  rpm for 40 min and the  plasma fracfionated with 
saturated neutral ammonium sulfate at 4°C. The globulin fraction precipitated at 55% satura- 
tion of  ammonium sulfate and  soluble at 25% was  obtained  and dialyzed  against 0.01 
sodium phosphate buffer at pH  8.0 containing sodium  ethylenediaminetetraacetate (EDTA) 
0.001 ~  and hexadimethrine bromide (H Br, Aldrich Chemical Co., Inc., Milwaukee, Wis.) 50 
#g/ml, before use. Plastic vessels were employed throughout. 
Chromatography.--Diethylaminoethyl  (DEAE)-Sephadex A-50 and carboxymethyl  (CM)- 
Sephadex  C-50  (Pharmacia Fine Chemicals,  Inc.,  Piscataway,  N.  J.)  were  prepared  as 
directed  in literature obtMned from  Pharmacia.  The  DEAE-Sephadex  was  hydrated  and 
charged and then rinsed thoroughly in H  Br, 50 #g/ml, and packed into a plastic column of 
3.7  )< 75 cm when 1 liter starting volume of plasma was used, or 3.1  X  62 cm when 500 ml 
was used. The gel was equilibrated with 0.01 ~t sodium phosphate buffer, pH 8.0  (starting 
buffer). The first chromatographic separation was performed using 1800 ml starting buffer in 
an open mixing Erlenmeyer flask and 1800 ml terminal buffer comprising starting buffer and 
sufficient NaC1 to yield 0.5 ~  concentration in an open Erlenmeyer flask. EDTA 0.001  ~  was 
included in both buffers. The two flasks were connected by a siphon tube. Samples of protein 
were applied to the column and rinsed in with starting buffer before beginning the gradient 
of NaC1. The second chromatographic separation consisted of DEAE-Sephadex A-50, prepared 
1Abbreviations used in  this  paper: ACD,  acid-citrate  anticoagulant; BAEe,  benzoyl-L- 
arginine ethyl  ester  H  C1; BSA,  bovine serum  albumin; H  Br,  hexadimethrine bromide; 
HGG,  human gamma  globulin; OMTI,  ovomucold  trypsin inhibitor; PKA,  prekallikrein 
activator; Pre-PKA, precursor of the prekMlikrein activator; TAMe, tosyl L-arginine methyl 
ester; TBS, Tris containing NaC1,  0.15  M. 
2 We are indebted to Mrs. Gunda Hiatt for her generous contributions of blood. 988  l~msT  COMPONENT OF  KININ-FORMING  SYSTIEI~[ IN  PLASMA 
and equilibrated as above in a plastic column of 2.6  X  35 cm. The same starting buffer (1800 
ml) was employed, but 1800 ml 0.15 M NaH2PO4  containing 0.20 x~ NaC1 and EDTA (0.001 
• t) was used as terminal buffer.  The third chromatographic separation was carried out on 
G-200 Sephadex, employing a column of 5  X  100 cm. The fourth separatory procedure in- 
volved CM-Sephadex C-50, packed in a plastic column of 2.6 X  35 cm. A buffer of citric acid 
and Na2HPO4, pH 5.85, #  =  0.01, was employed as starting buffer and a  citric acid-Na2 
HPO4 buffer, pH 7.4,/z =  0.037, containing NaC1, 0.3 M, as terminal buffer. Pooled fractions, 
rich in Pre-PKA, were concentrated after the first two steps by addition of sufficient  am- 
monium sulfate to yield 60% saturation. The concentrated protein was then dialyzed against 
the starting buffer of the next chromatographic procedure. 
Electrophoresls.--Disc  electrophoresis on polyacrylamide gel  (7 and 12%)  was conducted 
in gel cylinders of 70 X  6.5 mm or when larger recoveries were required, 110 X 9 mm accord- 
ing to the methods of Davis (3). Bromphenol blue and, when noted, bovine serum albumin 
(BSA)-125I  were incorporated as markers. At the termination of electrophoresis, the gels were 
removed from the siliconized  glass tubes and either stained in Coomassie blue in 20% tri- 
chloracetic acid or sliced in 2 mm sections for elution in tris(hydroxymethyl)aminomethane 
buffer (Tris)  containing NaC1, 0.15 M,  (TBS)  for 24 hr. 
Isodectrlc  Fractionatlon.--Performed  with  polyampholytes  (LKB  Instruments,  Inc., 
Bromma,  Sweden) as previously reported  (4). 
Ultracentrifugation.--Performed  in  linear  gradients containing 5-20%  sucrose in  TBS. 
Gradients of sucrose were prepared in a Buchler Instruments, Inc. (Fort Lee, N. J.), apparatus. 
Centrifugation was carried out in a Beckman Spinco L-4 ultracentrifuge (Beckman Instru- 
ments, Inc., Spinco Div., Palo Alto, Calif.)  at 65,000 rpm for 6 hr, or at 40,000 rpm 15 hr in 
an L- 1 ultracentrifuge. Internal markers of human gamma globulin (HGG)- 1311 and B SA- 1~51 
were included in the sample when sedimentation values of unknown proteins were calculated. 
Activation  of the Precursor of Prekallikrein  Activator (Pre-PKA, Hageman Factor, Factor 
XII).--The activation of Pre-PKA was performed in rIBS  buffer,  pH  7.5.  Pre-PKA was 
exposed to particles such as kaolin, diatomaceous earth, or to ellagic acid (K & K Laboratories 
Inc., Plainview, N. Y.). The particles were all previously washed in rIBS and suspended at 
5 mg/ml. 500/zg of kaolin was generally employed to activate preparations of Pre-PKA. The 
particles were shaken together with Pre-PKA at room temperature for 20 rain. This was found 
in preliminary observations to be optimal in time and temperature for binding all detectable 
Pre-PKA over the ordinary range of Pre-PKA concentration. When plasma kallikrein inhibitor 
was known to be present in the Pre-PKA preparation (generally until the second separation 
on DEAE-Sephadex A-50 was performed), the incubated preparations were centrifuged. The 
supernatant (containing the inhibitor) was removed and the sedimented particles were then 
assayed for bound Pre-PKA which was now in its active form, PKA, and for clot-promoting 
activity as outlined below. 
Trypsin was also used to activate Pre-PKA. 5 /zg/ml trypsin was incubated with Pre- 
PKA in TBS, pH 7.5, for 20 rain at 37°C. To inhibit the trypsin, but not subsequent com- 
ponents of  the kinin-forming system,  ovomucoid  trypsin inhibitor  (OMTI,  Worthington 
Biochemical Corp.,  Freehold, N.  J.),  50  #g//zg trypsin, was added.  Completeness of the 
activation of Pre-PKA was assessed by testing for any remaining Pre-PKA which would bind 
to kaolin, since in preliminary assays it was found that although Pre-PKA bound completely 
to kaolin,  PKA would not. 
Preparation of Prekallikrein.--Briefly described (4,  5)  and will  be  given in detail in  a 
separate publication. 3 Unless specified,  rabbit  or human prekallikrein was employed after 
chromatography on  DEAE-Sephaden A-50  twice. 
s Wuepper, K. D., and C. G. Cochrane. 1971. Plasma prekallikrein: isolation, characteriza- 
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Preparation of Kininogen.--Performed as noted previously (6), by chromatography twice 
on DEAE-Sephadex A-50, followed by CM-Sephadex C-50 and gel filtration chromatography 
on  Sephadex  G-200. 
Assays of the Activated Products of Pre-PKA (Hageman Factor).---Activated Pre-PKA, 
either bound to kaolin or in solution after treatment with trypsin, was assayed by its ability 
(a) to activate isolated prekallikrein, or (b) to promote clotting of factor XII-deficient human 
plasma. 
(a) After activation of Pre-PKA in the kaolin or trypsin, the product, PKA, was measured 
by adding prekallikrein. The mixture incubated at 37°C for 40 min. This converted prekalli- 
krein to its active enzyme form which was measured by its ability to cleave kinin from isolated 
kininogen or to hydrolyze 1 m~ benzoyl-L-arginine ethyl ester HC1  (BAEe, Mann Research 
Labs Inc., New York)  as' described previously.  ~ The hydrolysis of BAEe was measured by 
increasing absorption of the liberated benzoyl arginine at 253  am. 
Quantitation of PKA activity was performed in duplicate with dilutions of PKA. TBS was 
used as diluent. PKA (0.1 ml) was added to an excess of prekalfikrein (100 milliunits in 0.1 
ml). After an incubation period of 30 min, 37°C, 3.0 ml BAEe was added at 37°C. After 20 
rain,  the tubes were rapidly cooled and the OD at 253 nm recorded. If necessary, the tubes 
could be brought back to 37°C  and incubated for another interval of 20  min. Preliminary 
assays showed that the concentration of prekallikrein was sufficient  to yield a linear plot of 
activation by PKA over a range of PKA concentration. The hydrolysis of BAEe by kallikrein 
was found to be linear over a  range of approximately 0.075-0.300  OD units. A milliunit of 
PKA activity was defined as that amount in 0.1  ml that activated enough prekallikrein to 
yield an increase in OD at 253 nm of 0.001/min under the conditions noted above. 
The release of kinin from kininogen was assayed in a 5 ml muscle bath in Tyrode's-glucose 
solution at 37°C, using estrus rat uterus. Quantitative values were obtained by comparing the 
amplitude of contraction of the experimental samples with those produced by known quantities 
of synthetic bradykinin (Sandox, Inc., Hanover, N. J.). 
(b)  Clotting assays were also performed after activation of Pre-PKA with kaolin. These 
tests were carried out in plastic tubes, except where noted, and using factor XII-deficient 
human plasma. 100/~g kaolin (in 0.1 ml) that had been exposed to Pre-PKA were mixed with 
rabbit brain cephalin (0.05  ml of 1/50 dilution) obtained as a  gift from Dr.  Cecil Hougie, 
and 0.05 ml factor XII-deficient plasma in ACD. After incubation at 37°C for 8 min, 0.05 ml 
0.05 M CaC12 was added and a  timer started. The tubes were tilted until the formation of a 
firm clot was noted. The elapsed time was recorded. 100/~g untreated  kaolin was used as 
control. Human plasmas deficient in clotting factors XII, XI, and IX were generously contri- 
buted  by  S.  I.  Rapaport. 
Quantitative clotting assays were performed using dilutions of the clot-promoting material 
in TBS. 0.1 ml of the dilutions were added to cephalin and 0.05  ml factor XII-deficient or 
normal plasma as outlined above. A log-log plot was then drawn of the clotting time vs. the 
dilution used. 1 unit of clot-promoting activity was defined as that quantity in 0.1 ml yielding 
a  decrease of 25%  of control values. 
Ultrafiltration.--Performed in an Amicon cell using UM-10 membranes  (Amicon Corp., 
Lexington, Mass.). The cell and membrane were rinsed with H  Br, 50 #g/ml, before use and 
the functional capacity of the membrane tested with cytochrome C. 
Radioisotopes.--Labeling of proteins with  x25I or  131I was performed according to  the 
technique of McConahey and Dixon (7). 
RESULTS 
Isolation ot the First Component  of the Kinin-Forming System.  (Precursor  of 
the Prekallikrein Activator,  Pre-PKA, Hageman Factor, Clotting Factor XII).-- 
Globulins of human  and rabbit plasma were obtained and treated as  noted in 990  I~'IRST COMPONENT OF  KININ-I~ORMING SYSTEM IN  :PLASMA 
Materials  and Methods.  Analyses revealed the bulk  of Pre-PKA activity to 
be in the protein fraction soluble at 25 %  and precipitable at 55 %  saturation 
of ammonium sulfate. 
The elution of the globulin from the first column of DEAE-Sephadex A-50 
is  shown  in  Fig.  1.  Pre-PKA in  aliquots  of eluted fractions were  activated 
with kaolin and, as noted in the figure, eluted when the ionic strength reached 
0.13-0.15.  No  activity was  detected when kaolin was  omitted from the  test 
system, or when the kaolin was pretreated with H  Br (50 pg/500 #g kaolin), 
indicating that the molecule was in precursor form. The Pre-PKA was pooled 
and concentrated by precipitation with ammonium sulfate at 60% saturation 
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FZc.  1.  Chromatographic separation  of human  plasma  globulins on  DEAE-Sephadex 
A-50. The pH was maintained at 8.0 and a gradient of NaCI was used to elute the proteins. 
The tubes containing Pre-PKA are marked by cross-hatching. Prekallikrein ehited with the 
initial peak  of protein. 
and  applied  to  a  second  column  of DEAE-Sephadex  A-50.  The  elution  of 
Pre-PKA, shown in Fig. 2,  indicated that Pre-PKA separated from the bulk 
of contamintting proteins by this second elution from the  anionic  exchange 
medium.  Pre-PKA-containing  fractions  were  then  pooled,  concentrated  as 
before by precipitation with ammonium sulfate,  and applied to a  column of 
G-200 Sephadex. A  typical separation is shown in Fig. 3. Analysis of eluted 
fractions in 7 % polyacrylamide gel electrophoresis revealed that for both rab- 
bit  and  human  Pre-PKA,  several  anodally  migrating  contaminants  were 
removed by this procedure.  The contaminants  eluted both before and  after 
the  bulk  of Pre-PKA.  There remained  three  contaminants.  These  were  re- 
moved by chromatography on CM-Sephadex C-50. C.  G.  COCHRANE  AND  K.  D. WUEPPER  991 
The elution of Pre-PKA from CM-Sephadex C-50 is shown in Fig. 4.  Pre- 
PKA eluted when the effluent reached pH 6.9 and the ionic strength 0.20, By 
analysis on polyacrylamide gel electrophoresis, the Pre-PKA was found to be 
separated from the cathodal and anodal contaminants, leaving a single protein 
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FIG. 2.  Chromatographic separation on DEAE-Sephadex A-50 of fractions containing 
Pre-PKA. The fractions were obtained from  the first DEAE-Sephadex column  as noted in 
Fig. 1. Both a gradient of NaC1 and NaH2PO4 were employed to elute the proteins. 
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FIC. 3.  Gel filtration chromatography of fractions rich in Pre-PKA obtained from  the 
second separation on DEAE-Sephadex A-50 as noted in Fig. 2. By selecting fractions from 
the central portion of the peak, contaminants migrating in the anodal portion of an analytical 
polyacrylamide gel were  eliminated. 
band (Fig. 5).  Separate electrophoretic preparations were cut and eluted and, 
upon  activation with trypsin, revealed Pre-PKA activity associated with the 
band. This was found in both human  and rabbit Pre-PKA. 
The Pre-PKA so purified, upon treatment with kaolin, was found  capable 992  F]:RST COMPONENT OF  KININ-FORMING  SYSTEM IN  PLASMA 
of activating prekallikrein  leading to release of kinin from kininogen. Pre-PKA 
without  treatment  with  kaolin  was  ineffective  and  addition  of prekallikrein 
was essential for the release of kinin.  Quantitative  data on the release of kinin 
will be published  separately. 8 The yield of Pre-PKA was found  to be  15%  of 
the starting quantity. 
At this  point,  the  Pre-PKA molecules  became unstable  and  at  times  acti- 
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FIo. 4.  Cation  exchange chromatography  of CM-Sephadex C-50 of Pre:PKA rich  pro- 
reins. The proteins were obtained from gel filtration isolation of Pre-PKA as noted in Fig. 3. 
FIG. 5.  Analysis of human Pre-PKA (Hageman factor) on analytical polyacrylamide gel. 
The gel below was stained with 0.05% Coomassie blue, while a similar gel was sliced and the 
proteins eluted. An assay for the presence of Pre-PKA is shown. 
rated  spontaneously.  This  was most prevalent  with  human  Pre-PKA.  Con- 
centration  by  ultrafiltration,  negative  pressure  through  dialysis  tubing,  or 
lyophilization were all  found to promote activation  of unstable  preparations. 
Nevertheless,  by  conducting  separations  rapidly,  it  was  often  possible  to 
achieve  concentration  by  ultrafiltration,  retaining  the  bulk  of  Pre-PKA  in 
precursor form. 
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Factor  XII  (Hageman  Factor).--The  first  component  of  the  kinin-forming 
system  is  ptrrportedly  associated  with  clot-promoting  activity.  In  order  to 
examine  the  possibility  that  Pre-PKA  possessed  potential  clot-promoting 
activity, the eluates of each separatory column were assayed for clot-promoting 
ability  with  and  without  treatment  with  kaolin.  Upon  addition  of  kaolin, 
clot-promoting  activity  was  detected  (using  factor XII-deficient plasma  for 
clotting  assays)  in  areas  corresponding to the  presence  of Pre-PKA  (Fig.  1) 
TABLE  I 
Specificity of Clotting Activity of the First Component of the Kinin-Formlng System (Pre-PKA ) 
Pre-PKA*  Clotting plasma  Clotting time 
ml  rain 
0.01  Factor XII-deficient  2.83 
0.025  2.58 
--  19.50 
0.01  Factor XI-deficient  5.39 
0.025  5.28 
--  5.45 
0.01  Factor IX-deficient  19.50 
0.025  19.70 
--  19.70 
0.0l  Fibrlnogen 0.25%  > 38 
0.025  >38 
--  >38 
Thrombin IU  1.20 
* Human Pre-PKA activated with kaolin, 25 ~,g, 20 min at 22°C. Pre-PKA-kaolin mixture 
then added  to deficient plasma,  0.05 ml,  and cephalin, 0.05 ml.  Incubation with factors 
XII- and IX-deficient plasma carried out for 8 rain at 22°C, and with factor XI-deficient 
plasma 1 rain before adding 0.05 ml CaCI~ (0.05 M). Interval between addition of CaCh and 
the development of a firm clot was recorded. Factor XI-deficient plasma clotted in 2.2 min 
upon addition of partly purified human factor XI. 
This  was noted  for both  human  and  rabbit  Pre-PKA.  A  similar  association 
was found through each step in the isolation procedure. Activity was not found 
when kaolin was omitted.  Purified human Pre-PKA was then activated with 
kaolin  and  assayed  for  its  capacity  to  promote  clotting  of human  plasmas 
genetically deficient in factors XI and IX as well as purified human fibrinogen. 
The  results  are  given  in  Table  I.  They  indicate  that  activated  Pre-PKA 
promoted clotting of plasma deficient in factor XII, but not XI or IX or fibrino- 
gen. Rabbit Pre-PKA behaved similarly. 
Further  evidence indicating  a  relationship  of Pre-PKA  and  factor XII de- 994  FIRST  COMPONENT  OF  KININ-FORMING  SYSTEM:  IN  PLASMA 
rived  from  the  finding  that  Pre-PKA  activity  was  absent  in  factor  XII- 
deficient plasma obtained from two different individuals. Globulins soluble at 
25%  saturation of ammonium sulfate but precipitable at 50% were prepared 
from human plasma deficient in factor XII or factor XI. These were then sedi- 
mented in  sucrose density  gradients,  and  activation of Pre-PKA attempted 
with trypsin. Pre-PKA activity was readily detected in the sedimented globu- 
lins of factor XI- but not factor XII-deficient plasma (Fig. 6). In these tests, 
the  samples  used  were  deliberately excessive in  quantity  in  order  to  allow 
detection of even small quantities of Pre-PKA. The apparent rapid sedimenta- 
tion of Pre-PKA in the factor XI-deficient plasma is probably explained, as 
noted  below,  by  the  presence  of kallikrein inhibitors  in  the  4--4.5S  region. 
Similarly, no Pre-PKA was detected in factor XII-deficient plasma chromato- 
graphed on DEAE-Sephadex A-50. 
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FIG.  6.  Assay of Pre-PKA activity in human plasma globulins deficient in clotting factors 
XII and XI. Globulins were obtained by precipitation from plasma with ammonium sulfate, 
and sedimented in a sucrose gradient, 40,000 rpm, 16 hr. Pre-PKA was detected in globulins 
of Factor XI-but not factor XII-deficient plasma. 
The data  suggest  an identity of Pre-PKA  and  Hageman  factor.  Physical 
characterization of the two activities was then performed to assess this further. 
Physical  Characterization of Pre-PKA  and  Clot-Promoting  (ttageman  Fac- 
tor) Activities.--Assays  of physical  characteristics were performed  by gel fil- 
tration,  isoelectric  fractionafion  on  polyampholytes,  and  sedimentation  in 
density gradients of sucrose. The results are shown in Figs. 7-9. As indicated, 
As indicated, the eluting patterns of Hageman factor activities in each case 
were superimposed revealing identical properties. When the volmne of elution 
of Pre-PKA  and factor XII  activities  from G-200  Sephadex  (Fig.  7)  were 
plotted as a function of the log molecular weight or diffusion coefficient (8), a 
molecular weight  of  110,000-120,000  and  a  diffusion coefficient of  4.25  M 
10  -~  cm2/sec  could be  assigned  to  each.  Sedimentation  in  sucrose  density 
gradients indicated a sedimentation rate of 4.5-4.6S (Fig. 8). The values were 
true of both rabbit and human proteins. Isoelectric fractionation revealed an C.  G.  COCHRANE  AND  K. D. WUEPPER  995 
isoelectric point of 6.1S for rabbit Pre-PKA (Fig. 9). Pre-PKA and Factor XII 
activities could,  therefore,  not  be separated by these  techniques.  Activation 
of both Pre-PKA and Factor XII was achieved with either kaolin or trypsin. 
It should be noted that when sedimentation in sucrose gradients was per- 
formed with  whole plasma or globulins,  the measured sedimentation  rate of 
Pre-PKA  was  6-7S.  In  experiments  designed  to discern  the  reason  for  this 
rapid sedimentation rate, an inhibitor(s)  of kallikrein was (were) found in the 
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FIG. 8.  Sedimentation of human Pre-PKA  (Hageman factor) in a gradient of sucrose, 5- 
20%.  Sedimentation was conducted at 50,000 rpm for 6 hr. 
crude plasma or globulins that sediments in the 4-4.5S region. This inhibitor 
prevented  detection  of Pre-PKA  in  that  region  leaving measurable  activity 
only in  the more rapidly sedimenfing zones.  Recentrifugation  of the  rapidly 
sedimenting Pre-PKA revealed a 4.5S rate of sedimentation.  The inhibitor(s) 
was (were) found to block the activity of kallikrein, trypsin, and thrombin. 
The possibility was considered  that  the  superimposable elution  profiles of 
Pre-PKA  and factor XII could be explained on the basis  that  the  clot-pro- 
moting factor was first activated by treatment with kaolin or trypsin, and this 
then activated the Pre-PKA. The Pre-PKA activity would,  therefore,  corre- 
spond precisely to the position of clot-promoting factor. To test this possibil- 996  IrlRST  COMPONENT  OF  KININ-FORMING  SYSTEI~[  IN  PLASMA 
ity, definite quantities  of protein from each shoulder of the elution profile of 
the column of G-200 Sephadex, shown in Fig. 3, were mixed with protein from 
the  center  of the  peak or  from either  shoulder  region.  Activation  was  then 
obtained with kaolin and the quantity of Pre-PKA was measured. The values 
were expressed in units  of PKA activity.  These values were compared with 
those  expected  from the  arithmetical  sums  of  the  units  of  each when  com- 
bined. Presumably, if the clotting factor was required to activate the Pre-PKA, 
a  marked  excess  of  measured  activity  over  that  expected  would  result.  As 
shown in Table II, the measured and expected values were comparable. This 
indicated  that  the  two  activities  eluted  from  the  gel  filtration  column  to- 
gether. 
Since the evidence accumulated strongly indicates that the precursor mole- 
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FIG.  9.  Isoelectric  fractionation  of  rabbit  Pre-PKA  in polyampholytes.  Separation  was 
performed  over a  30 hr period. 
cule  of  the  prekallikrein  activator is  Hageman  factor  (clotting  factor XII), 
the more commonly used term I-Iageman factor will be employed hereafter. 
Molecular Changes Associated with  the Activation  of Hageman  Factor (Pre- 
PKA).--In  previous  studies  in  this  laboratory  (9),  diatomaceous  earth  was 
used to bind and activate Hageman factor from whole human or rabbit plasma. 
The two activities were then eluted,  after washing of the particles,  with  2 
NaCI;  however,  exposure  of isolated Hageman factor  to  kaolin  or  diatoma- 
ceous  earth  yielded  activation  of  the  PKA  and  clotting  activities,  but  the 
active moieties were so firmly bound to the particles as to resist elution with 
2 M NaC1  or mild  acid conditions.  Attention  was turned,  therefore,  to  other 
methods of activating the first component:  (a)  activating Hageman factor by 
treatment with trypsin, and (b) allowing spontaneous activation to occur. 
(a) Activation by treatment with trypsin:  50 ml of human or rabbit Hageman 
factor was obtained from the peak tubes of activity of a column of CM-Sepha- C.  G.  COCHRANE AND  K.  D.  WUEPPER  997 
dex, i.e., from the fourth step  of purification. The protein was concentrated 
approximately  tenfold by  ultrafiltration.  One-half  of  the  protein  was  then 
treated with trypsin as noted in Materials and Methods, and the other half 
was kept for analysis of Hageman factor. 2 ml of the trypsin-treated portion 
was reacted with OMTI for assays of PKA activity, while the remainder was 
examined for migration of the split products of Hageman factor in polyacryla- 
mide gel electrophoresis (OMTI contains proteins that migrate in the anodal 
region  of polyacrylamide gels  and  it  was  therefore  omitted).  Even  though 
abundant PKA activity was present  after treatment with trypsin, it would 
not bind to kaolin as evidenced by the lack of hydrolysis of prekallikrein and 
its inability to promote clotting of factor XII-deficient plasma after washing 
of the kaolin in TBS. All PKA activity resided in the supernatant. This indi- 
cated that  trypsin  activated  the Hageman factor  completely. The  trypsin- 
TABLE  II 
Comparison of the Measured and Expected Quantity of Pre-PKA Obtained by Combining Various 
Fractions Eluting from G-200 Sephadex 
Tube numbers combined*  PKA expected  PKA measured 
milliuni~  mdliunits 
147  +  155  82  73 
147  +  162  115  105 
155  +  162  93.5  100 
* The gel filtration column is that shown in Fig. 3. The tube numbers correspond to the 
following elution volumes: tube 147, 122  ml; tube 155, 130 ml; tube 162, 145  ml.  Volumes 
used in the assay: tube 147, 0.1 ml; tube 155, 0.01 ml; tube 162, 0.2 ml. 
treated Hageman factor, after addition of OMTI, was examined in three ways 
for the presence of split products: 1 ml was fractionated by gel filtration on a 
column of G-200  Sephadex; 0.2  ml was  assayed by ultracentrifugation in a 
gradient of sucrose; and 0.1 ml was tested in duplicate in polyacrylamide gel 
electrophoresis. The fractions were assayed for PKA and clotting activities. 
The results of gel filtration are shown in Fig. 10. Both activities were found 
in the same fractions yielding superimposable patterns of elution. The volume 
of elution of these activities was plotted as a function of log molecular weight, 
proteins of known molecular size having been used to calibrate the column. 
PKA and clot-promoting activities eluted at  a  molecular weight of 30,000- 
32,000.  Ultracentrifugation of the trypsinized Hageman factor revealed that 
the  active PKA  and  clot-promoting fractions sedimented together  at  2.6S. 
The patterns  of  sedimentation and  gel  filtration of PKA were  identical to 
those previously reported from this laboratory (4, 9, 10). 
Electrophoresis in  polyacrylamide gels  showed  that  the  Hageman  factor 
had been cleaved so that a protein band no longer appeared in the cathodal 998  FIRST  COMPONENT  O~F  KININ-FORMING  SYSTEM  IN  PLASMA 
section of the gel.  Instead, four new and fainter bands appeared in the anodal 
region between BSA-Z25I and brompheno] blue tracking dye (Fig. 11). Another 
band was apparent in the midportion of the gel. Not infrequently,  only three 
anodal protein bands appeared. Elution of a gel that was processed in parallel 
and cut into 1.5 mm sections showed both PKA and clot-promoting activities 
in the far anodal region. The results using human and rabbit Hageman factor 
were similar. 
(b) Spontaneous activation of Hagemanfactor:  It was essential to know if the 
activation of Hageman factor isolated from human or rabbit plasma could be 
achieved by means other than trypsinization since fragments obtained by this 
method may not be similar to those achieved by more physiologic activation. 
As noted previously, Hageman factor activated spontaneously at times during 
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FI6.  10.  Gel filtration of fragments of activated rabbit Hageman factor (Pre-PKA) on 
G-200 Sephadex. The elution of fractions containing PKA and clot-promoting activity are 
shown eluting after BSA marker. The molecular weight of the two activities was noted to be 
32,000 when the elution volume was plotted as a function of the log molecular weight. 
concentration  by  ultrafiltration  after  chromatography  on  CM-Sephadex. 
Accordingly, 50 ml of human and rabbit Hageman factor obtained from CM- 
Sephadex  were  allowed  to  activate spontaneously  at  4°C.  The  three  assays 
performed in the previous section were also employed, i.e. gel filtration, ultra- 
centrifugation,  and  electrophoresis  in  polyacrylamide  gel.  The  results  were 
quite similar to those noted in the previous section. PKA and clot-promoting 
activities  eluted  together  in  the  30,000  molecular region  in  chromatography 
on  Sephadex  G-200,  and  both  sedimented  in  the  2.6S  region.  Two or  three 
anodal  bands  in  the prealbumin region were  generally found  by acrylamide 
gel  electrophoresis,  one  of  them  coincident  with  PKA  and  clot-promoting 
activity.  Activation  was  never  complete,  however,  and  a  small  amount  of 
Hageman  factor  was  generally  found  in  the  appropriat  e  fractions  (i.e.,  as 
defined earlier in this article). 
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of Hageman Factor.--In previous  studies  (4,  19),  we have reported that  the 
activation product  of Hageman factor,  i.e.  PKA,  possessed  little  detectable 
clot-promoting activity in the face of abundant PKA activity. The PKA had 
been obtained by exposure of chelated plasma to diatomaceous earth followed 
by elution of PKA with 2 •  NaC1. The parent molecule on the other hand was 
rich  in  clot-promoting  activity  when  activated  by  kaolin.  To  examine  this 
question  further, rabbit Hageman factor obtained from the fourth step of the 
purification process,  i.e.  from CM-Sephadex,  was activated with kaolin.  The 
clotting and PKA capacities of the activated Hageman factor were compared 
with the same properties of purified PKA. The PKA was obtained from spon- 
taneously activated Hageman factor, the PKA being purified by disc electro- 
phoresis in polyacrylamide. When compared on the basis of equal quantities 
of  prekallikrein  activating  capacity  (measured  in  milliunits),  the  clot-pro- 
FIG. 11.  Analytic polyacrylamide gel  electrophoresis of  activated  human  Hageman 
factor (Pre-PKA) (upper gel). Comparison is made with unactivated Hageman factor (lower 
gel). The positions of PKA and clotting factor are noted in the upper gel corresponding to a 
band of protein. These activities were obtained from a duplicate gel carried in parallel, sliced, 
and eluted. While four prealbumin bands are shown, more frequently only two or three were 
observed. 
moting activity of the kaolin-treated Hageman factor was found to be about 
50-fold greater than that of the fully cleaved product,  PKA. 
DISCUSSION 
Studies  are  presented  on  the  isolation,  characterization,  and  activation  of 
the precursor form of the first component of the kinin-forming system in rabbit 
and human plasma.  Functionally,  this molecule is  the  precursor  of the  acti- 
vator of prekallikrein  (Pre-PKA) which,  as the evidence has shown,  is identi- 
cal to the initial  component of the intrinsic  clotting system, Hageman factor 
(factor XII). The protein was found to be a molecule of 110,000-120,000  tool 
wt  as  determined  by gel  filtration,  to  sediment  at  4.5-4.6S,  and  to  possess 
electrophoretic  charge  characteristics  of  /3-globulin  with  an  isoelectric  point 
of 6.1. The discrepancy between sedimentation velocity and gel filtration data 
may be explained on the basis of molecular asymmetry and/or  carbohydrate 
content.  Present  information  does  not  allow for a  distinction  between  these 1000  FIRST  COMPONENT  OF  KININ-FORMING  SYSTEM  IN  PLASMA 
possibilities.  Isolation of  this  component  was  made  possible  by preventing 
contact  of  the  plasma  and  subsequent  fractions with  anything but  plastic 
vessels,  by pretreating  all surfaces  and separatory media  (except  cation ex- 
change gels) with H Br, and by reducing the time of preparation to a minimum. 
Of considerable interest is the finding that human and rabbit Hageman factor 
bind firmly to an anion exchange medium (DEAE-Sephadex A-50)  and to a 
cation  exchange  medium  (CM-Sephadex  C-50)  as  well.  Presumably,  the 
molecule possesses  strong  charge densities,  both  positive  and  negative,  and 
advantage was taken of this property in the isolation procedure. 
Pre-PKA  and Clotting Factor XII.--Evidence  strongly suggested  an iden- 
tity of Pre-PKA and  clotting factor XlI (Hageman factor). The highly puri- 
fied Pre-PKA was found upon activation to promote clotting of factor XII- 
but not Factor XI- or Factor IX-deficient human plasma or fibrinogen. Pre- 
PKA bound readily and completely to kaolin, ellagic acid, or  diatomaceous 
earth in 0.01 M EDTA and acquired the clot-promoting activity in the process. 
Of particular note, Pre-PKA was not detectable in plasma of two individuals 
genetically deficient  in  factor  XII.  Pre-PKA  and  clot-promoting  activities 
eluted identically from anion and cation exchange media and were found to 
have an identical isoelectric point (6.1). The volume of elution in gel filtration 
(= tool wt 110,000-120,000)  and the sedimentation rates  (4.5-4.6S)  were the 
same. 
The dual nomenclature appears redundant in the face of such evidence, and 
even though immunologic techniques have not yet been employed to identify 
each form of the molecule, one is justified in equating the two. The commonly 
used name, Hageman factor, has therefore been applied. 
A link between the first component of the kinin-forming system and factor 
XlI has been known for years. Margolis and Bishop (11-14)  and Webster and 
Ratnoff (15)  demonstrated that plasma from individuals genetically deficient 
in factor XlI  (Hageman factor) would not generate kinins upon exposure to 
glass.  In  addition,  Kaplan  and  Austen  (16, 17)  have  demonstrated Factor 
XlI activity associated with the activator of prekallikrein isolated by electro- 
phoresis in polyacrylamide gels. 
Activation  of Hageman Factor.--The  process  of activation of the molecule 
was  associated with fragmentation into several  daughter molecules.  Activa- 
tion was  achieved by  treatment with  trypsin,  exposure  to kaolin,  glass,  di- 
atomaceous earth, or by allowing Hageman factor in highly purified form to 
activate  spontaneously  at  4°C.  After  fragmentation,  two  active  properties 
were acquired: (a)  the capacity to convert prekallikrein (prokininogenase) to 
its enzymatically active state (PKA activity), and (b) the capacity to promote 
clotting of factor XII- but not Factor XI-  or Factor IX-deficient plasma. 
These two activities could not be separated by disc gel electrophoresis, gel fil- 
tration  chromatography, or  by ultracentrifugation in  a  gradient  of sucrose. C.  G.  COCHRANE  AND  K.  D.  WUEPPER  i001 
Thus, their physical characteristics were identical: 32,000  tool wt,  2.6S  sedi- 
mentation velocity, and a prealbumin electrophoretic mobility in  acrylamide 
gels. 
It was of interest that exposure of Hageman factor to surfaces such as that 
provided by kaolin generated immense clot-promoting activity relative to that 
of the PKA fragment. A comparison of the quantity of clot-promoting capacity 
of Hageman factor activated by kaolin and of the fragment PKA revealed the 
former to possess more than 50-fold greater clotting capacity than the latter. 
In  support  of  this  finding is  the  observation  (unpublished)  that  enzymatic 
cleavage of Hageman factor to PKA in solution generates full PKA activity 
but very little clot-promoting activity. It would appear that the capacity to 
promote  clotting is  diminished when  the  PKA fragment is  generated. This 
may be explained by a loss of functional activity in clotting on the PKA frag- 
ment, or by inhibition of the majority of clot-promoting sites associated with 
a different fragment. 
The description and physical parameters of PKA have been reported pre- 
viously  from  this  laboratory  (4,  9,  10). The  association  of  clot-promoting 
activity with PKA was observed first by Kaplan and Austen (16).  Movat et 
al.  (18-20)  have also reported the presence of a prekallikrein activator in the 
prealbumin region of acrylamide gels  after electrophoresis.  We have  recently 
described  the  enzymatic nature of PKA  (21) which will be  dealt with in  a 
separate  article2  The  possibility  that  the  other  anodal  fragments  possess 
biologic activity is of great interest. 
While the sedimentation rate of Hageman factor in the present studies is 
close to that (4.5-5.5S)  reported by Donaldson and Ratnoff (22), the sedimen- 
tation of active Hageman factor  is  different.  Using  ellagic  acid  to  activate 
Hageman factor, these authors found a rapid sedimentation rate, the activated 
molecule reaching the bottom of the tube of a  sucrose gradient of 10-40%  in 
less than 100 rain at 100,000 g. The rapid sedimentation was noted even when 
the preparation  was centrifuged in 5%  bovine albumin, 0.5 •  NaC1,  or 5 M 
urea. The reason for the discrepancy is not clear, but may be related to the 
different methods of activation of Hagelnan factor. Schoenmakers et al.  (23) 
and Haanen et al. (24) have reported a sedimentation rate of 7.1 for activated 
bovine Hageman factor. The Hageman factor was prepared  by  eluting the 
active material from glass, followed by further purification. In acrylamide gels, 
the clot-promoting activity moved slowly toward the anode as opposed to the 
prealbumin migration of the Hageman factor fragment reported in the present 
study.  The  bovine  clotting  factor  (23, 24)  was  also  associated  with  BAEe 
esterase activity which was not true of activated human and rabbit Hageman 
factor in the present studies. The bovine protein activated prekallikrein  (25). 
This, together with its BAEe and TAMe hydrolytic properties, indicated that 
the Hageman factor was  already active.  Its  activity was  inhibited by lima 1002  FIRST  COMPONENT  OP  KININ-FORMING  SYSTEM  IN  PLASMA 
bean trypsin inhibitor. Thus, the physical properties  and the data on inhibi- 
tion of the bovine protein are markedly different from those of the human and 
rabbit active product, PKA. We have also noted that a clot-promoting factor 
could be  obtained by elution from diatomaceous earth that  was exposed to 
whole plasma  (26).  After purification, this factor possessed BAEe hydrolytic 
activity, sedimented at about 7S, and migrated in acrylamide gel at the same 
position as that  of Schoenmakers et  al.  (23, 24).  These  two  clot-promoting 
substances  share many features, including method of preparation,  the  only 
difference being that the 7S protein in our hams would clot factor XI- as well 
as  factor XII-deficient plasma.  This has  also  been  noted by  Movat  et  al. 
(20). Of particular interest, the clot-promoting fractions eluted from diatoma- 
ceous earth  as noted above  were found by us to  activate Hageman factor, 
releasing from it PKA (26). It will be interesting to find whether this Hageman 
factor activator in plasma is  related to plasmin, found recently by Kaplan 
and Austen (17) and by Burrowes (27) to generate PKA from its precursor. 
SUMMARY 
The isolation and characterization of the first component of the kinin-form- 
ing system in human and rabbit plasma are presented. Functionally, the mole- 
cule is the precursor of the activator of prekallikrein (Pre-PKA) and evidence 
is presented that it is identical with Hageman factor (clotting factor XII).  The 
component from each plasma possessed similar characteristics. "1his molecule 
was found to have a  mol wt of 110,000  and sedimentation rate  of 4.6S.  It 
migrated in electrophoresis as a/~-globulin, having an isoelectric point of 6.1. 
Upon activation with glass, kaolin, diatomaceous earth, ellagic acid, or trypsin, 
the activated molecule converted purified prekallikrein  (prokininogenase)  to 
the active enzyme. 
Clot-promoting activity was associated with the capacity to activate pre- 
kallikrein through each procedure of isolation. The clot-promoting factor was 
in precursor form, requiring treatment with kaolin or trypsin to gain activity. 
Evidence  indicated  that  the  protein  was  Hageman factor  (factor  XII):  it 
promoted clotting of factor XII-deficient, but not Factor XI- or IX-deficient 
plasma, and did not convert fibrinogen to fibrin  it bound to and was activated 
by kaolin or other negatively charged particles in the presence  of chelating 
agents; the activation by kaolin could be prevented by pretreating the kaolin 
with hexadimethrine bromide  (H  Br);  prekallikrein-activating and  clot-pro- 
moting activities were identical in their physical properties; and the prekalli- 
krein activator could not be detected in Hageman factor-deficient plasma. 
Activation of Hageman factor was accompanied by cleavage of the mole- 
cule into several  fragments,  one  of which  possessed  prekallikrein-activating 
(PKA) and clot-promoting properties. The PKA fragment sedimented at 2.6S 
and by gel  filtration was  found to have  a  molecular weight of 32,000.  The C.  G.  COCttRANE  AND  K.  D.  WUEPPER  1003 
PKA possessed only 1/g 0  the clot-promoting capacity of the freshly activated 
native molecule. 
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